Literature DB >> 10830141

Promising approaches in acute leukemia.

J Cortes1, H M Kantarjian.   

Abstract

In the last few decades, there has been a significant improvement in the prognosis of patients with acute leukemias. Still, the majority of patients succumb to these diseases. In recent years there has been a great surge in the understanding of the molecular mechanisms of disease which have provided us with new targets for anti-leukemia therapy. These range from chemotherapeutic agents with novel mechanisms of action, such as topoisomerase I inhibitors or demethylating agents, to reversal of drug-resistance mechanisms, to monoclonal antibodies directed against specific antigens, and targeted therapy that inhibit the function of molecules such as tyrosine kinases or Ras. The research on many of these agents is still in the early phases, but these new approaches offer the promise of finding a cure for the majority of patients with leukemia in the near future. Here we describe some of the promising approaches that are currently being investigated in the treatment of acute leukemias.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10830141     DOI: 10.1023/a:1006392116024

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  258 in total

Review 1.  Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity.

Authors:  E C Guinan; J G Gribben; V A Boussiotis; G J Freeman; L M Nadler
Journal:  Blood       Date:  1994-11-15       Impact factor: 22.113

2.  High remission induction (traditional sino-western HOAP) regimen for acute nonlymphocytic leukemia.

Authors: 
Journal:  Chin Med J (Engl)       Date:  1980-08       Impact factor: 2.628

3.  Effect of melphalan against self-renewal capacity of leukemic progenitors in acute myeloblastic leukemia.

Authors:  C Demur; M Chiron; S Saivin; M Attal; N Dastugue; C Bousquet; J L Galinier; P Colombies; G Laurent
Journal:  Leukemia       Date:  1992-03       Impact factor: 11.528

4.  Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors.

Authors:  L D Mayer; M B Bally; H Loughrey; D Masin; P R Cullis
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

5.  Leukemic cell differentiation in vivo and in vitro: arrest of proliferation parallels the differentiation induced by the antileukemic drug Harringtonine.

Authors:  A W Boyd; J R Sullivan
Journal:  Blood       Date:  1984-02       Impact factor: 22.113

6.  Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.

Authors:  E J Feldman; K P Seiter; T Ahmed; P Baskind; Z A Arlin
Journal:  Leukemia       Date:  1996-01       Impact factor: 11.528

7.  Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study.

Authors:  B Camitta; B Leventhal; S Lauer; J J Shuster; S Adair; J Casper; C Civin; M Graham; D Mahoney; L Munoz
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

8.  Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice.

Authors:  Y Xu; Q Xu; M G Rosenblum; D A Scheinberg
Journal:  Leukemia       Date:  1996-02       Impact factor: 11.528

9.  Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia.

Authors:  E Schneider; K H Cowan; H Bader; S Toomey; G N Schwartz; J E Karp; P J Burke; S H Kaufmann
Journal:  Blood       Date:  1995-01-01       Impact factor: 22.113

10.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

Authors:  D G Maloney; T M Liles; D K Czerwinski; C Waldichuk; J Rosenberg; A Grillo-Lopez; R Levy
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.